What is the appropriate dosing and administration of oseltamivir (Tamiflu) for treating acute influenza in adults and children, including renal dose adjustments?

Oseltamivir (Tamiflu) Dosing and Administration

For adults and adolescents ≥13 years with acute influenza, administer oseltamivir 75 mg orally twice daily for 5 days; for children ≥1 year, use weight-based dosing twice daily for 5 days, with renal dose adjustments required for creatinine clearance 10-30 mL/min (reduce to 75 mg once daily for treatment). 1, 2, 3

Treatment Dosing

Adults and Adolescents (≥13 years)

• Standard dose: 75 mg orally twice daily for 5 days 1, 2, 3
• Can be administered without regard to meals, though taking with food may improve GI tolerability 1

Pediatric Patients (≥1 year)

Weight-based dosing (twice daily for 5 days): 1, 2

• ≤15 kg (≤33 lb): 30 mg twice daily
• >15-23 kg (33-51 lb): 45 mg twice daily
• >23-40 kg (51-88 lb): 60 mg twice daily
• >40 kg (>88 lb): 75 mg twice daily

Infants (<1 year)

The most recent 2024 AAP guidelines provide age-stratified dosing 2:

For term infants:

• 9-11 months: 3.5 mg/kg/dose twice daily
• 0-8 months: 3.0 mg/kg/dose twice daily

For preterm infants (based on postmenstrual age): 1, 2

• <38 weeks PMA: 1.0 mg/kg/dose twice daily
• 38-40 weeks PMA: 1.5 mg/kg/dose twice daily
• >40 weeks PMA: 3.0 mg/kg/dose twice daily

Important caveat: Oseltamivir is FDA-approved for children as young as 2 weeks, but use in infants <3 months has limited safety data. 1, 2 Preterm infants have slower renal clearance and require lower doses than term infants to avoid toxic drug concentrations. 4

Prophylaxis Dosing

Adults and Adolescents

• Post-exposure: 75 mg once daily for 10 days 1, 2
• Community outbreak: 75 mg once daily for up to 6 weeks 3

Pediatric Patients (≥1 year)

Use same weight-based doses as treatment, but once daily instead of twice daily for 10 days (or up to 6 weeks during community outbreaks) 1, 2

Infants

• 3-11 months: Same mg/kg dose as treatment, but once daily 1, 2
• <3 months: Not recommended unless situation judged critical due to limited data 4, 5

Renal Dose Adjustments

For creatinine clearance 10-30 mL/min: 4, 1, 3

Treatment:

• 75 mg once daily for 5 days (instead of twice daily)

Prophylaxis:

• 30 mg once daily for 10 days, OR
• 75 mg once every other day for 10 days (5 total doses)

Critical consideration: Current renal dosing recommendations may be inadequate. Recent pharmacokinetic data suggest that patients with mild-to-moderate renal impairment may not achieve therapeutic concentrations early enough in infection when using reduced doses. 6 The first dose should remain 75 mg to ensure rapid therapeutic levels, with subsequent doses adjusted for renal function.

Pediatric renal dosing: No specific pediatric renal dosing is provided in the FDA label. 3 For children >40 kg who qualify for adult dosing, use the adult renal adjustments above. 2

Formulations and Administration

Available forms: 1, 3

• Capsules: 30 mg, 45 mg, 75 mg
• Oral suspension: 6 mg/mL concentration (after reconstitution from powder)

Suspension dosing volumes (6 mg/mL concentration): 1

• 30 mg = 5 mL
• 45 mg = 7.5 mL
• 60 mg = 10 mL
• 75 mg = 12.5 mL

If commercial suspension unavailable: Capsules can be opened and contents mixed with sweetened liquid or compounded by pharmacies to 6 mg/mL concentration. 1 For infants <1 year, use appropriate measuring device (3-mL or 5-mL oral syringe) rather than supplied syringe. 2

Clinical Considerations

Timing of Treatment

Treatment is most effective when initiated within 48 hours of symptom onset. 3, 7, 8 However, treatment after 48 hours should still be offered to patients with moderate-to-severe or progressive disease, as some benefit has been demonstrated. 1

Who Should Receive Treatment

The AAP and CDC recommend antiviral treatment for: 4, 1

• Any child hospitalized with presumed influenza
• Children at high risk for complications (regardless of vaccination status)
• Children with severe, complicated, or progressive illness

High-risk groups include: Children <2 years, those with chronic medical conditions (asthma, cardiac disease, immunosuppression, neurologic disorders), and pregnant women. 4

Efficacy Evidence

In children with laboratory-confirmed influenza, oseltamivir reduces illness duration by approximately 36 hours (26% reduction) and decreases acute otitis media by 44% in children 1-5 years. 1, 7 In adults, treatment reduces illness duration by 29-35 hours when started within 36 hours of symptom onset. 8

Important limitation: Despite widespread guideline recommendations for hospitalized children, high-quality randomized trial evidence is lacking in this population, leading to significant practice variability. 9

Common Adverse Effects

• Nausea and vomiting (most common, occurring in ~5-6% of patients) 1, 7
• Vomiting is more common in children than adults
• Taking with food may reduce GI symptoms 1

Serious Warnings

• Hypersensitivity reactions: Discontinue if allergic reactions occur 2, 3
• Neuropsychiatric events: Patients with influenza, particularly children, may experience confusion or abnormal behavior early in illness. Monitor for signs of abnormal behavior. 3

Drug Interactions

Live attenuated influenza vaccine (intranasal): 3

• Do not administer vaccine until 48 hours after stopping oseltamivir
• Do not give oseltamivir until 2 weeks after vaccine administration (unless medically indicated)

Resistance Considerations

Resistance to oseltamivir can emerge, though rates remain low for most circulating strains. 4, 10 Continuous surveillance is essential. Resistance is particularly problematic in critically ill ICU patients. 11